Common Contracts
4 similar Collaborative Development and License Agreement contracts by Enanta Pharmaceuticals Inc
COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT by and between ENANTA PHARMACEUTICALS, INC. and ABBOTT LABORATORIES November 27, 2006 Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote...Collaborative Development and License Agreement • February 9th, 2016 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (“Agreement”) is made as of [●], 20 , by and among Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), the investors named on the Schedule of Investors attached hereto (the “Initial Investors”) and the additional investors added from time to time to the Schedule of Investors in accordance with Section 23 below (the “Additional Investors,” and together with the Initial Investors, the “Investors”).
Enanta has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT by and between ENANTA...Collaborative Development and License Agreement • February 5th, 2013 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (“Agreement”) is made as of [ — ], 20 , by and among Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), the investors named on the Schedule of Investors attached hereto (the “Initial Investors”) and the additional investors added from time to time to the Schedule of Investors in accordance with Section 23 below (the “Additional Investors,” and together with the Initial Investors, the “Investors”).
Enanta has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT by and between ENANTA...Collaborative Development and License Agreement • December 18th, 2012 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (“Agreement”) is made as of [ — ], 20 , by and among Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), the investors named on the Schedule of Investors attached hereto (the “Initial Investors”) and the additional investors added from time to time to the Schedule of Investors in accordance with Section 23 below (the “Additional Investors,” and together with the Initial Investors, the “Investors”).
Enanta has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT by and between ENANTA...Collaborative Development and License Agreement • November 6th, 2012 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • New York
ABBOTT PARK, Ill., and WATERTOWN, Mass., Dec XX, 2006 – Abbott and Enanta Pharmaceuticals announced today that the companies have signed a worldwide agreement to develop and commercialize hepatitis C virus (HCV) NS3 and NS3/4A protease inhibitors. Enanta has discovered several HCV protease inhibitors that have demonstrated attractive efficacy and pharmacokinetic profiles in pre-clinical studies.
